Navigation Links
QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
Date:1/3/2008

Novel non-estrogen oral therapy in development for menopausal symptoms

ANN ARBOR, Mich., Jan. 3 /PRNewswire/ -- QuatRx Pharmaceuticals Company today announced positive results from a pivotal Phase 3 study of Ophena(TM) (ospemifene) to treat postmenopausal women with vulvovaginal atrophy, a common condition associated with menopause. Top line data show that the multi-center, double-blind, placebo-controlled study successfully met all of its co-primary endpoints. The study was conducted in 80 U.S. centers and involved more than 800 women. Full results of the study are being submitted to an upcoming scientific meeting for release later in 2008.

Ophena(TM) is a novel selective estrogen receptor modulator (SERM) that is being studied as a treatment for women with postmenopausal vaginal syndrome (PVS), also known as vaginal atrophy. PVS is a common condition in postmenopausal women characterized by symptoms such as vaginal dryness, irritation and pain associated with sexual intercourse. The only currently FDA approved products for this condition all contain the hormone estrogen. However, many women and their physicians avoid using estrogen-containing products due to concerns about the risks of such therapy identified in the Women's Health Initiative (WHI) and other studies.

"These results are very exciting and we believe demonstrate that Ophena(TM) has the potential to bring clear clinical benefit to women affected by PVS, many of whom have had only estrogen therapy as a treatment option for their condition to date," said Robert L. Zerbe, M.D., chief executive officer and president of QuatRx. "We believe Ophena(TM) could provide the first non- estrogen prescription treatment alternative for this condition. QuatRx is well positioned to continue with our plans to advance this exciting product to commercialization, pending regulatory review and approval."

This pivotal Phase 3 study was designed to evaluate the efficacy of Ophena(TM) versus p
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015 Valencia Technologies Corporation ... patient with its radically small device for the ... early results in this randomized, double-blinded, controlled trial are ... of confidence that it will succeed in a large ... early clinical results, Valencia has ...
(Date:3/2/2015)... 2, 2015  CytomX, a biotechnology company developing ... announced the creation of scientific and clinical advisory ... the fields of cancer immunotherapy and antibody drug ... will provide guidance to CytomX on the development ... and Probody drug conjugates. The company identified advisors ...
(Date:3/2/2015)... , March 2, 2015 Leading patient ... kicking off the 2015 One Million Strong ... national campaign will raise awareness and funds for colorectal ... than one million colorectal cancer survivors living in ... disease with great strength and courage every day. ...
Breaking Medicine Technology:Valencia Technologies Implants its 48th Patient, Continues Equity Crowdfunding 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 3Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 2Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 3Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 4Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 5
... counts its partnership initiative among its most valuable ... for Hospices in Sub-Saharan Africa) has successfully created ... and organizations providing care in 15 different African ...  They are working collaboratively to expand access to ...
... 2011  Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) ... Neurology Foundation (CNF) in support of the 3rd annual ... October 24-30, 2011, in conjunction with the Child Neurology ... As part of this education effort, CNF has developed ...
Cached Medicine Technology:FHSSA Launches New Campaign to Partner US Hospices with Programs in Sub-Saharan Africa 2Questcor and Child Neurology Foundation Support the 3rd Annual Infantile Spasms (IS) Awareness Week 2Questcor and Child Neurology Foundation Support the 3rd Annual Infantile Spasms (IS) Awareness Week 3Questcor and Child Neurology Foundation Support the 3rd Annual Infantile Spasms (IS) Awareness Week 4
(Date:3/2/2015)... 02, 2015 ProvidaStaff has ... its educational healthcare division to EDU Healthcare ... services to school systems and students nationwide. , “ProvidaStaff ... school districts throughout the country,” said Angela M. Lewis, ... a better organization and the introduction of EDU Healthcare ...
(Date:3/1/2015)... Clearwater, Florida (PRWEB) March 02, 2015 ... market their services and manage their practices ... offer an integrated all-inclusive solution. The ... development program and a medical practice management ... success and long-term financial sustainability. A referral ...
(Date:3/1/2015)... 2015 Women’s Excellence now offers ... (OAB) symptoms, such as a strong need to urinate with ... medication (anticholinergic) does not work well enough or cannot be ... another approach to targeting the source of OAB, the bladder ... and bladder muscle, blocking the signals that trigger OAB. ...
(Date:3/1/2015)... March 01, 2015 A federal ... http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) scheduled to go to trial in ... a witness to provide testimony regarding the role ... of the Profemur device, Bernstein Liebhard LLP comments. ... Court, Northern District of Iowa on February 25th, ...
(Date:3/1/2015)... Atlanta, GA (PRWEB) March 01, 2015 ... of Evelyn King and Carolyn Roddy to the professional ... Director of Compliance, graduated from The Ohio State University-Mortiz ... over 15 years of experience working with several Fortune ... specifically in the area of corporate benefits. Her experiences ...
Breaking Medicine News(10 mins):Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 4Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2
... Bangladesh are exposed to unsafe levels of arsenic in their ... serious diseases, according to the World Health Organization (WHO). ... surface, many people in Bangladesh have installed deep wells to ... In recent years, farmers have begun using the deep, uncontaminated ...
... , ... on board a flight from London to Los Angeles helped stabilize a flight attendant who ... in Montreal to care for this victim. , ... (Vocus) May 28, 2010 -- Dr. Semira Bayati was onboard United Airlines flight ...
... inherited lymphedema associated with lymphatic function has been discovered ... researchers at the University of Pittsburgh Graduate School of Public ... the American Journal of Human Genetics . ... an accumulation of fluid in a blocked or damaged lymphatic ...
... deformed bone into place instead of breaking it, researchers ... new technique for the treatment of bunions appears to ... for standard invasive surgery. , The novel procedure -- ... the foot and ankle program and an assistant professor ...
... ... called the Hospital Charitable Service Awards, has been created to celebrate and encourage the ... ... A new national awards program, called the Hospital Charitable Service Awards , ...
... Online Brand ... ... Peltz Shoes has partnered with local SEO Tampa Fla., firm Bayshore Solutions to ... usability, overall sense of online purchase security and search engine optimization that followed best practices., , ...
Cached Medicine News:Health News:Scientists offer solutions to arsenic groundwater poisoning in southern Asia 2Health News:Scientists offer solutions to arsenic groundwater poisoning in southern Asia 3Health News:Scientists offer solutions to arsenic groundwater poisoning in southern Asia 4Health News:Orange County Plastic Surgeon Helps Stabilize Wounded Flight Attendant Requiring an Emergency Landing 2Health News:Orange County Plastic Surgeon Helps Stabilize Wounded Flight Attendant Requiring an Emergency Landing 3Health News:Pitt researchers discover gene mutation linked to lymphatic dysfunction 2Health News:New Bunion Procedure Aims to Replace Invasive Foot Surgery 2Health News:Nominations Sought for Charitable Hospital Programs that ‘Give Back' 2Health News:Nominations Sought for Charitable Hospital Programs that ‘Give Back' 3Health News:Local SEO Tampa Firm Bayshore Solutions Bring Revenue Results to Premier Online Shoe Store Peltz Shoes 2Health News:Local SEO Tampa Firm Bayshore Solutions Bring Revenue Results to Premier Online Shoe Store Peltz Shoes 3
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
Ruschelit® PVC. Murphy eye-nasoral. X-ray opaque line. Graduated. Single use. Sterile...
Ruschelit® PVC. Magill tip - nasoral. X-ray opaque line. Graduated. Single use. Sterile...
... Tube with stylet inside. Sterile, Latex ... Rusch endotracheal tube with a preloaded ... saving you time and storage space. ... easy identification and has a stopper ...
Medicine Products: